Schering's diagnostic sales beat expectations:
This article was originally published in Clinica
German company Schering had full-year diagnostic sales of Euro1,040 million ($1,013 million), up 18% and "far ahead of expectations", the company said. Berlin-based Schering attributed the good result to a substantial growth in volume sales, as well as the recovery of the Asian currencies and relatively stable prices in Japan. X-ray contrast media sales increased 17% to Euro646 million, while sales of Magnevist, a contrast media for MRI, rose 18% to Euro233 million. During the year, the company expanded into radiopharmaceuticals with the acquisition of US company Diatide and CIS of France.
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.